AstraZeneca collaborates on cancer nanomedicine

04/22/2013 | PharmaTimes (U.K.)

AstraZeneca and Bind Therapeutics will collaborate on a targeted, programmable, nanotechnology cancer treatment involving a kinase inhibitor. The nanoparticles, which Bind calls Accurins, selectively accumulate, causing higher drug concentrations at the site of a tumor while sparing healthy tissue. AstraZeneca is also working with Horizon Discovery on a kinase therapy that targets the K-Ras mutation in various cancers, including of the lung and colon.

View Full Article in:

PharmaTimes (U.K.)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice President, Science and Regulatory Affairs
American Beverage Association
Washington, DC
Senior Manager of Medical Management
Network Health
Medford, MA
MEDICAL SCIENCE LIAISON - 14000002RO
Abbott
Columbus, OH
Manager, Medical Management
Network Health
Medford, MA
Executive Medical Director
Aspirus Network Inc
Wausau, WI